VNDA (Vanda Pharma) Future Price to Earnings

Vanda Pharmaceuticals (VNDA) specializes in the development and commercialization of medications for the correction of mental disorders. The business relies on holding exclusive rights to psychiatric and sleep therapies, which guarantees consistent demand. This chart of the F/PE ratio currently reflects a level of 0.00. High pricing is sustained by the company's dominance in the rare disease segment.

Market Cap to Projected Earnings: Vanda Pharma (VNDA) for 07/04/2022 - 11/14/2026

Metric breakdowns and analytics for Vanda (VNDA)

- current price and projected stock value:

Stock Quotes Vanda Pharmaceuticals Inc.|VNDA - Fair Value Consensus

- business market valuation indicators:

Market Value Vanda Pharma|VNDA - Full Business Value

- balance sheet equity data:

Net Assets per Single Share Vanda Pharmaceuticals|VNDA - Book Valuation of Business|Market Cap to Net Assets Ratio vandapharma.com|VNDA - Company Assets

- company total debt and liquidity indicators:

- company profitability and valuation multiples indicators:

VNDA - Net Profit|Expected Profit Vanda Pharmaceuticals|VNDA - Price to Earnings Multiple|Forward P/E Multiple Vanda Pharmaceuticals Inc|VNDA - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Vanda Pharma|VNDA - Operating profit EBITDA|Net earnings per share for the last 12 months Vanda Pharmaceuticals|VNDA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months vandapharma.com|VNDA - Earnings per share trend in current year|Earnings growth forecast for next year Vanda Pharmaceuticals

- revenue and sales proceeds data:

VNDA - Company Sales Revenue|Projected Sales Volume Vanda Pharmaceuticals Inc.|VNDA - P/S Multiple|Price-to-Projected Revenue Ratio Vanda Pharma

Fundamental valuation:VNDA Vanda Pharmaceuticals Inc.

Investors should employ position stress testing to assess capital resilience against market volatility. Vanda Pharmaceuticals (VNDA) is developing the biopharmaceutical sector by integrating strict environmental standards into its supply chains. The ratio of the current price to expected earnings on the company's forward P/E chart reflects market yield expectations. An increasing multiple signals inflated expectations, while a decrease indicates stagnation. This allows for an assessment of the cost-effectiveness of laboratory energy efficiency.

Competitors of Vanda Pharmaceuticals (VNDA)

Projected Price to Earnings ALKS (Alkermes)|AVDL (Avadel Pharmaceuticals PLC) - Future Price to Earnings Multiple|Future Price to Earnings atai Life Sciences Corp ATAI|GHRS (GH Research Group) - Price to Expected Earnings Ratio|MNMD - Future Price to Earnings|Market Cap to Projected Earnings compasspathways.com CMPS|LBRX (LB Pharmaceuticals) - Projected Price to Earnings|Projected Price to Earnings Ratio Bright Minds Bio (DRUG)|CYBN (Cybin Inc) - Forward P/E Multiple|Projected Price to Earnings Alto Neuroscience Corp (ANRO)|Forward P/E Multiple NRXP|CING (cingulate.com) - Future Price to Earnings Multiple|Future Price to Earnings Silo Pharma, Inc. SILO|China Pharma Holdings Inc. (CPHI) - Projected Price to Earnings Ratio|CMND: Projected Price to Earnings|PBM: Future Price to Earnings|SPRC: Forward P/E Multiple|seelostherapeutics.com (SEEL) - Forward P/E Multiple|Future Price to Earnings Virpax Pharmaceuticals Inc.|Price to Future Earnings Ratio KRTX (Karuna Therapeutics Inc)